Blood plasma microRNAs (miRNAs) are emerging as a clinically useful tool for non-invasive detection and prognosis estimation in various cancer types including pancreatic ductal adenocarcinoma (PDAC). The aim of the present study was to provide an independent validation of circulating miRNAs identified in previous studies as diagnostic and/or prognostic biomarkers in PDAC. Based on the literature search, 6 miRNAs were chosen as candidates for independent validation; miR-21-5p, miR-375, miR-155, miR-17-5p, miR-126-5p and miR-1290. Validation of these miRNAs was performed in a cohort of 25 patients with PDAC undergoing surgical resection and 24 healthy donors. Plasma levels of miRNAs were determined using quantitative real-time PCR. We confirmed significantly higher levels of all tested miRNA in blood plasma of PDAC patients in comparison to healthy controls with miR-21-5p showing the highest analytical performance (p<0.001; AUC>0.99). Increased levels of miR-21-5p (p=0.045) and miR-375 (p=0.013) were significantly associated with overall survival. Multivariate analysis demonstrated that miR-21-5p is a significant unfavorable prognostic factor independent on other clinical variables including adjuvant chemotherapy (hazard ratio 2.95; 95% CI 1.06-8.18; p=0.038). Our preliminary data indicate promising diagnostic and prognostic utility of plasma miR-21-5p in PDAC patients.

中文翻译：

---

术前血浆miR-21-5p是胰腺导管腺癌手术切除患者的敏感生物标志物和独立预后因素。

血浆microRNA（miRNA）逐渐成为一种临床有用的工具，可用于各种类型的癌症（包括胰腺导管腺癌（PDAC））中的非侵入性检测和预后评估。本研究的目的是提供对先前研究中鉴定为PDAC中诊断和/或预后生物标志物的循环miRNA的独立验证。在文献检索的基础上，选择了6个miRNA作为独立验证的候选对象。miR-21-5p，miR-375，miR-155，miR-17-5p，miR-126-5p和miR-1290。这些miRNA的验证是在25名接受手术切除的PDAC患者和24名健康供体中进行的。使用定量实时PCR测定血浆中miRNA的水平。我们确认，与健康对照者相比，PDAC患者血浆中所有测试的miRNA的水平明显高于健康对照者，miR-21-5p显示出最高的分析性能（p <0.001； AUC> 0.99）。miR-21-5p（p = 0.045）和miR-375（p = 0.013）水平升高与总体生存率显着相关。多变量分析表明，miR-21-5p是独立于其他临床变量（包括辅助化疗）的重要不良预后因素（危险比2.95； 95％CI 1.06-8.18； p = 0.038）。我们的初步数据表明血浆miR-21-5p在PDAC患者中具有广阔的诊断和预后价值。013）与总体生存率显着相关。多变量分析表明，miR-21-5p是独立于其他临床变量（包括辅助化疗）的重要不良预后因素（危险比2.95； 95％CI 1.06-8.18； p = 0.038）。我们的初步数据表明血浆miR-21-5p在PDAC患者中具有广阔的诊断和预后价值。013）与总体生存率显着相关。多变量分析表明，miR-21-5p是独立于其他临床变量（包括辅助化疗）的重要不良预后因素（危险比2.95； 95％CI 1.06-8.18； p = 0.038）。我们的初步数据表明血浆miR-21-5p在PDAC患者中具有广阔的诊断和预后价值。